Vimizim (elosulfase alfa) (Elosulfase Alfa INJECTION, SOLUTION, CONCENTRATE) 5 mg/5mL

Vimizim (elosulfase alfa) is an FDA-approved orphan drug developed by BioMarin Pharmaceutical Inc. for the treatment of Mucopolysaccharidosis IVA (MPS IVA), also known as Morquio A Syndrome. It is administered intravenously and represents a significant therapeutic advance in the rare genetic disorder category.

Strength

5 mg/5mL

Pack Size

1 VIAL in 1 CARTON (68135-100-01) / 5 mL in 1 VIAL

Manufacturer / TM Owner

BioMarin Pharmaceutical Inc.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Vimizim is indicated for patients with Mucopolysaccharidosis IVA (MPS IVA/Morquio A Syndrome), a rare lysosomal storage disorder caused by deficiency of the enzyme N-acetylgalactosamine-6-sulfatase (GALNS). This enzyme deficiency leads to accumulation of glycosaminoglycans in various tissues, causing progressive skeletal deformities, respiratory compromise, cardiac involvement, and reduced mobility. Vimizim is an enzyme replacement therapy (ERT) that provides the deficient GALNS enzyme, helping to reduce the accumulation of substrate materials. The drug is used to improve walking capacity and reduce pain in pediatric and adult patients with confirmed MPS IVA diagnosis. Treatment aims to slow disease progression, improve functional outcomes, and enhance quality of life in this severely debilitating genetic condition.

Side Effects

Common adverse events associated with Vimizim include infusion-related reactions such as fever, chills, flushing, headache, nausea, and vomiting. Serious adverse events may include anaphylaxis, severe infusion reactions, and immune-mediated responses. Patients may develop anti-drug antibodies over time. Monitoring requirements include regular assessment of infusion tolerance, vital signs during and after administration, and periodic evaluation of clinical efficacy through walking capacity tests and pain assessments. Premedication with antihistamines and corticosteroids is often recommended to minimize infusion reactions.

Precautions & Warnings

Vimizim is contraindicated in patients with known hypersensitivity to elosulfase alfa or any excipients. Use with caution in patients with compromised cardiac or respiratory function, as MPS IVA commonly affects these systems. Pregnancy category data is limited; use only if benefits outweigh risks. Pediatric patients represent the primary population, though safety in infants under 5 years requires careful consideration. No specific dose adjustments are required for renal or hepatic impairment, but monitoring is advised. Patients with severe immune reactions or anaphylaxis history require careful risk-benefit assessment before treatment initiation.

Avoid Interactions

No major drug-drug interactions have been formally documented with Vimizim. However, concurrent use of other medications affecting immune function or infusion tolerance should be monitored. Antihistamines and corticosteroids used for premedication do not contraindicate Vimizim use. Patients receiving other enzyme replacement therapies or substrate reduction therapies should inform healthcare providers. No specific food or substance interactions are known; however, adequate hydration is recommended during treatment.

Frequently Asked Questions

Vimizim is used to treat Mucopolysaccharidosis IVA (Morquio A Syndrome), a rare genetic lysosomal storage disorder. It works by replacing the deficient GALNS enzyme, helping reduce the buildup of harmful substances in the body and improving walking capacity and reducing pain in affected patients.

Vimizim is administered as an intravenous infusion, typically on a weekly basis. The infusion is given in a healthcare setting where patients can be monitored for infusion reactions. Premedication with antihistamines and corticosteroids is often provided to minimize adverse reactions.

Common side effects include infusion-related reactions such as fever, chills, flushing, headache, nausea, and vomiting. Most reactions are mild to moderate and manageable with premedication. Serious reactions including anaphylaxis are rare but require immediate medical attention.

Vimizim is manufactured by BioMarin Pharmaceutical Inc., a leading biopharmaceutical company specializing in rare genetic diseases and orphan drug development.

Yes, Vimizim is an FDA-approved orphan drug designated for the treatment of Mucopolysaccharidosis IVA. Orphan drug status recognizes its development for a rare disease affecting fewer than 200,000 people in the United States, providing regulatory incentives and market exclusivity.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.